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Background: In-hospital and long term outcomes of patients admitted to the hospital for acute
exacerbation of bronchiectasis (AEB) has been evaluated in only a limited fashion. The resulting
debilitation after an AEB can increase mortality. This study aims to evaluate the factors associ-
ated with mortality in patients admitted with an acute exacerbation of bronchiectasis (AEB).
Methods: All charts of the patients admitted between 2003 and 2006 with an AEB were
reviewed through an electronic database. Demographics, sputum cultures, pulmonary func-
tions tests and other factors associated with long-term mortality were examined. The social
security death index was used to determine long term mortality (http://ssdi.genealogy.
rootsweb.com).
Results: Forty-three patients (13 men and 30 women) with a mean age of 71.8  11.8 were
studied. The hospital mortality was 9% and one-year mortality was 30% with a median survival
of 46.6 months. Variables associated with mortality were male gender (female vs. male (HR),
0.36; (CI), 0.14e0.98; pZ 0.045), use of systemic steroids (with vs. without steroids HR, 3.12;
CI 1.08e9.02; pZ 0.036), decreased FEV1.0% predicted (HR, 0.96; CI 0.92e0.999; pZ 0.042),
elevated creatinine (HR, 2.36; CI 1.093e5.10; pZ 0.029), history of smoking (HR, 0.283; CI
0.097e0.825; pZ 0.021), and mechanical ventilation (HR, 66.011; CI 6.64e656.76;
pZ 0.0004).on of bronchiectasis; COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test.
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ventilation, history of smoking, and acute use of systemic steroids during the hospitalization
were associated with an increased risk of mortality.
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Bronchiectasis, a disease that was first recognized by
Laennec in the early nineteenth century, is characterized
by a pathologic dilation of the bronchi and bronchioles1
with destruction of the elastic and muscular components of
the walls.2 The prevalence of the disease is believed to be
decreasing due to increased usage of antibiotics for
pulmonary infections, reduced incidence and prevalence of
tuberculosis, and childhood illnesses such as measles and
pertussis.3 The disease is characterized by a repetitive
cycle of inflammation followed by infections causing
structural damage to the bronchi and bronchioles.4
There is limited data on the mortality after an acute
exacerbation of bronchiectasis (AEB). Recently, two studies
outside of the United States reported the survival in
patients admitted to the medical intensive care unit (MICU)
with an AEB. In these studies, the mortality rate was 40% at
one year and 60% at four years.5,6 Furthermore, there is still
a significant mortality in non-hospitalized patients with
bronchiectasis that varies from 13% to 25%.7e9 There is no
recent information in the USA of outcomes including
mortality in patients admitted to the hospital with AEB. The
goal of this study is to evaluate the factors associated with
mortality both during the admission and after discharge for
all patients admitted to a teaching hospital in Central Texas
during a 3-year period.
Methods
Patient population
A retrospective single center observational cohort study
was done at Scott and White Hospital (Temple, Texas) for
all patients with diagnosis of bronchiectasis admitted for
AEB between January 1, 2003 and December 31, 2006. All
patients were identified by electronic medical records using
diagnostic codes for bronchiectasis (ICD-9 diagnosis codes
494.0 e Bronchiectasis w/o acute exacerbation and 494.1 e
Bronchiectasis w/acute exacerbation). Patients were
required to have the following factors to be included in the
study: a radiographic diagnosis of bronchiectasis, age
greater than 18 years of age, and met criteria for an AEB as
defined by O’Donnell modified criteria.10 Patients with
history of cystic fibrosis, bronchial asthma, or chronic
obstructive pulmonary disease (COPD) without bronchiec-
tasis were excluded.
Criteria for AEB
A modified criteria for an AEB was used. It was based on
O’Donnell’s criteria which required having four of the
following nine criteria: change in sputum production,
increased dyspnea, increased cough, fever (temper-
ature> 38.0 C), increased wheezing, fatigue or malaise,radiographic evidence of new infiltrate, change in breath
sounds, and reduction of FEV1.0 or FVC by 10% in comparison
to a previously recorded (PFTs).9 Pulmonary function tests
(PFTs) were omitted because our cohort did not have them
performed at the onset or during the exacerbation. There-
fore, the O’Donnell’s modified criteria used in this study
required four of eight criteria to be considered an AEB.
Radiographic criteria
Patients were diagnosed by computer tomography (CT) of
the thorax based on standard criteria previously reported
and chest radiograph was used in patients diagnosed prior
to the use of CT scans.11e13
Data collected
Two investigators (JDF and ST) reviewed the electronic
records and collected the following variables: demo-
graphics, smoking history, diagnosis of COPD by a physician,
sputum or tracheal cultures on admission, arterial blood
gas, platelet count, hemoglobin, bilirubin, creatinine, need
for mechanical ventilation, and pulmonary function test
prior to admission.
Statistical analysis
Outcomes
Outcomes were based on both hospital and long term
mortality. Hospital mortality was evaluated by using the
electronic medical record. All-cause mortality was evalu-
ated by using the Social Security Death Index (http://ssdi.
genealogy.rootsweb.com) on October 16, 2007 to deter-
mine the date of death and the length of survival from
hospital admission.14 All subjects who were not deceased
on this date were identified as alive in our study, and
survival time (in months) for those patients were censored.
Statistical analysis
Demographic characteristics and variables of interest were
summarized by survival status (survivor vs. non-survivor)
using descriptive statistics: mean (SD) for continuous vari-
ables and frequency (proportion) for categorical variables.
Survival curves and the median survival time were esti-
mated by the KaplaneMeier method. Univariate survival
analysis was completed for all factors using the Cox
proportional hazard model, and survival curves of
subgroups of each factor were compared using the Mantele
Haenszel log-rank test. Multivariate Cox proportional
hazards model were applied to the factors with p< 0.1 in
the univariate models. A log-rank test was utilized to
compare subgroups of significant factors detected by
univariate analysis and clinically relevant factors. A p-value
of less than 0.05 was used to detect the statistical
818 J.D. Finklea et al.significance. SAS 9.1.3 (SAS Institute INC, Cary, NC) was
used for data management and statistical analysis.Results
One hundred and seventy-three patients were admitted to
the hospital with the diagnosis of bronchiectasis during
the study period. Forty-three patients met criteria for an
AEB and had a radiographic diagnosis (98% by CT and 2% by
chest radiograph). The mean age was 71.8 11.8, 30
patients were females (69.8%), and all were Caucasian.
Forty-two patients (33.3%) smoked or were actively
smoking and 49% had a diagnosis of COPD. Twenty-six
(60%) patients had PFTs done, the FEV1.0 was 1.3 0.5 L
with a FEV1.0 predicted of 53.4 19.3% and FVC predicted
66.1 19.5%. The in-hospital mortality rate was 9%, the
one-year mortality rate was 30%, and the median survival
was 46.6 months. Twelve patients (28%) received long
term oxygen and three patients required mechanical
ventilation. The average length of stay in the non-survivor
group was 7.06 2.98 days and the survivor group was
4.70 3.98 days (Table 1).
Eighty-one percent of the patients (35 patients) had
cultures of the respiratory secretions and in 8 patients
a sputum sample could not be obtained. Of the patients that
had cultures of the secretions, 69% were expectorated
sputum, 9% were obtained via bronchoscopy, and 2% by blind
tracheal aspirate. A pathogenic organism was found in 49%.
Themost common organismswere Pseudomonas. aeruginosa
mucoid strain (23%) and non-mucoid strain (16%).
The average score based on O’Donnell’s criteria for
acute exacerbation of bronchiectasis was 6.27 out of total
of 9. The most common symptoms associated with exac-
erbation were change in the characteristics of sputum
(88%), increase cough (84%), and increase dyspnea (72%).
Risk factors for mortality using a univariate Cox propor-
tional hazard model were male gender (female vs. male
Hazard Ratio (HR), 0.36; Confidence Interval (CI), 0.14e0.98;
pZ 0.045), the use of systemic steroids during the AEB (HR,
3.12; 1.08e9.02; pZ 0.036), increased creatinine (HR, 2.36;
CI 1.09e5.10; pZ 0.029), FEV1.0% predicted prior to admis-
sion (HR, 0.96; CI 0.92e0.99; pZ 0.042), history of smoking
(HR, 3.53, CI 1.21e10.30; pZ 0.021), and requirement for
mechanical ventilation (HR 66.011; OR 6.64e656.7;
pZ 0.0004). Hypoxia, hypercapnia, long term oxygen
therapy prior to admission, and the presence of a specific
pathogen were not associated with mortality. The same
variables showed a significant effect on survival based on
univariate analysis using a log-rank test.
Multivariate Cox proportional hazard model results were
done using significant variables from the univariate anal-
ysis, however they did not reach statistical significance.
Subgroups formed by significant factors detected by
univariate analysis and a clinically relevant factor such as
age at hospitalization were compared using a log-rank test.
Due to the small sample size, survival curves of subgroups
formed by two significant factors at a time were compared.
Subgroups were analyzed to determine the effect of age
and the acute use of systemic steroids during the hospi-
talization on survival. The patients were divided into four
groups (70 or older with acute steroid therapy, 70 or olderwithout acute steroid therapy, younger than 70 with acute
steroid therapy, and younger than 70 without acute steroid
therapy). There was a significant difference in survival
found between the four groups (pZ 0.0474) (Fig. 1). The
patient least likely to survive were patients greater than 70
years of age and who acutely received systemic steroids.Discussion
The important findings in this study were: admission to the
hospital with AEB was associated with a significant hospital
(9%) and one year mortality (30%), with a median survival of
46.6 months. P. aeruginosa was the most common path-
ogen. The usage of systemic steroids during hospital
admission, increased creatinine, FEV1.0% predicted,
mechanical ventilation, history of smoking, and male
gender were associated with an increased mortality.
This study highlights the association of high mortality at
one year in patients with an AEB admitted to an acute care
hospital. The mortality at one year in our study is very
similar to the mortality reported by Dupont et al. (40%) and
by Alzeer et al. (34%) in patients admitted to the MICU with
an AEB, despite the fact that our patients were admitted
predominantly to the hospital ward and only 3 were
admitted to the ICU.5,6
In our study, we also found that male gender was asso-
ciated with an increased mortality rate. This was contrary
to Pasteur et al. who found a predilection to females with
bronchiectasis, but lung damage developed at the same
rate in both genders.15 Gender did not affect mortality in
the two previous studies done in the ICU with AEB.5,6 The
percentage of females in the ICU study were similar
(Dupont et al. 58% female, Alzeer et al. 60% female, and
our study 68% female).
Also, in our study the requirement of intubation resulted
in 100% mortality (3 out of 3 requiring intubation died
during the hospitalization). One could consider this as
a marker for poor prognosis, but due to the small sample it
should be interpreted cautiously.
The FEV1.0% predicted in our population was
53.4 19.3% and was similar to the FEV1.0% predicted
reported by other authors.7,10,16 Many studies attempted
correlating the disease severity with other associated
factors in the decline in FEV1.0% predicted. For example,
Roberts et al. found that the degree of airflow obstruction
correlated with the degree of radiographic findings on CT,
specifically the severity of bronchial wall thickening and
disease of the small airways.17 In another study of bron-
chiectasis patients infected with P. aeruginosa there was no
association with the decline in FEV1.0% predicted.
18 The
patients who died in our study had a FEV1.0% predicted prior
to admission of 40.9 13.5% and those who survived were
58.1 19.3%. This reached statistical significance, but
should be interpreted with caution due to 40% of the
patients not having PFTs prior to the admission.
The results showed a significant difference comparing
creatinine levels between the twogroups (Survivor 0.9 0.5;
Non-survivor1.2 0.5). This small change in creatinine could
possibly demonstrateworsening renal function during an AEB
which could lead to an increased mortality. Decreased renal
function has been used as a marker of poor outcomes in prior
Table 1 Demographics and other characteristics.
Total (nZ 43) Non-survivor (nZ 16) Survivor (nZ 27)
Age (years) 71.8 11.8 76.1 7.7 69.3 13.2
Gender
Female 30(69.8%) 8(50.0%) 22(81.5%)
Male 13(30.2%) 8(50.0%) 5(18.5%%)
Smoking history 14(33.3%) 8(53.3%) 6(22.2%)
COPD 21(48.8%) 10(62.5%) 11(40.7%)
Mechanical Ventilation 3(7.0%) 3(18.8%) 0(0.0%)
Length of Hospital Admission 5.60 3.77 days 7.06 2.98 days 4.70 3.98 days
P. aeruginosa non-mucoid strain 10(23.3%) 4(25.0%) 6(22.2%)
P. aeruginosa mucoid strain 7(16.3%) 2(12.5%) 5(18.5%)
First HCO3 mmol/L 28.5 10.4 28.7 12.3 28.3 5.6
First O2 saturation % 94.4 5.3% 95.1 5.7% 92.8 4.2%
First pO2 mm/Hg 98.9 72.6 107.8 84.1 79.0 38.0
First pCO2 mm/Hg 65.7 47.6 74.9 54.3 45.0 19.6
First pH 7.4 0.1 7.3 0.1 7.4 0.1
Bilirubin (mg/dL) 0.8 0.5 1.0 0.7 0.7 0.3
Creatinine (mg/dL) 1.0 0.5 1.2 0.5 0.9 0.5
Highest Hemoglobin (g/dL) 12.6 1.4 12.4 1.7 12.7 1.2
Lowest Platelets (10e9/L) 230.6 90.5 206.2 118.8 246.2 64.7
Infiltrate on Chest
Radiograph or CT Thorax
in the 1st 48 h
14(32.6%) 7(43.8%) 7 (25.9%)
Systemic Steroids
during Hospitalization
20 (46.5%) 11(68.8%) 9(33.3%)
Inhaled steroids
prior to admission
13(29.5%) 5(31.3%) 8(29.6%)
FEV1.0 (L) 1.3 0.5 1.3 0.4 1.4 0.5
FEV1.0% predicted 53.4 19.3 40.9 13.5 58.1 19.3
FEV1.0/FVC 60.3 12.9 59.4 16.9 60.7 11.6
DLCO (ml/min/mmHg) 13.8 4.8 11.1 5.2 15.3 4.1
DLCO % predicted 58.8 18.6 48.2 21.8 64.7 14.7
Antibiotics during
the hospitalization
Ceftazidime 3 (7.0) 1 (6.3) 2 (7.4)
Imipenemecilastatin 3 (7.0) 1 (6.3) 2 (7.4)
Piperacillinetazobactam 8 (18.6) 5 (31.3) 3 (11.1)
Tobramycin 19 (44.2) 7 (43.8) 12 (44.4)
Vancomycin 3 (7.0) 2 (12.5) 1 (3.7)
Figure 1 Survival curves in patients with AEB; pZ 0.0474.
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Therefore, worsening renal function in AEB may be
associated with a poor prognosis.
The acute use of systemic glucocorticoids in patients
with an AEB has not been evaluated.22,23 In this retro-
spective review of patients with an AEB, we found an
increased mortality associated with the acute use of
systemic glucortocoids during the hospitalization. Although
acute usage of steroids has not been studied in bronchiec-
tasis it has been evaluated in the COPD population.
Niewoehner et al. found in the COPD population that
there were increased rates of infection in the group that
had an extended course of glucocorticoid group (8 week),
but this was not statistically significant in comparison to the
placebo and short course group (2 week).24 Unfortunately,
because of the nature of the study a steroid protocol for
determining which individual should receive steroids in
patients with AEB was not organized. Therefore, the dosage
of steroids given to each patient varied and was not
820 J.D. Finklea et al.consistently documented in the electronic medical record.
The evaluation of death via the social security death index
prevented determination of the etiology of death.
A limited number of patients were on inhaled steroids
during our study so this will make it difficult to draw
specific conclusions on their usage. In the past, inhaled
steroids have been beneficial in patients who are in
a steady state bronchiectasis, but no data were found on
patients with an AEB using inhaled steroids.25,26
Smoking has been known to be associated with lung
disease.27 In this study it was found that smoking was
associated with an increased mortality. Unfortunately, due
to it retrospective nature, pack years were not consistently
documented. Possible causes are defects in the ability to
clear secretions predisposing them to an increased risk of
infections28 and increased inflammation of the lung
parenchyma caused by the toxic chemicals in tobacco.29,30
KaplaneMeier survival curves were used in the study to
graphically demonstrate a trend with patient’s age (greater
than or less than 70) and acute use of systemic glucocor-
ticoid usage. A p-value based on a log-rank test comparing
the 4 survival curves reached statistical significance. It
illustrated that elderly patients who received steroids
during the hospitalization tend to have an increased
mortality. The cause of this trend for increased mortality
could be consistent with the information discussed above in
patients who received steroids.
The most important limitations of this study are its
retrospective nature and the relatively small sample size.
Decreased body mass index (BMI) had been associated in
bronchiectasis patients with an increased mortality rate,
unfortunately height was not documented in our medical
records so this variable could not be evaluated.7
In conclusion, the one-year mortality rate of 30% after
an AEB was consistent with previous studies.5,6 Patients
with the highest mortality rates had the following factors:
male gender, acutely used systemic steroids during the
hospitalization, increased creatinine, decreased FEV1.0%
predicted, history of smoking, and use of mechanical
ventilation during the hospital admission. To our knowledge
this was the first study that suggested there may be an
association between acute usage of systemic steroids and
mortality in patients admitted with an AEB. Finally, this
study demonstrated that this disease can be quite devas-
tating, but unfortunately there is a limited amount of
research on it at this time.
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